LifeMD has closed a senior secured revolving credit facility with Citizens Bank, N.A., providing up to $50 million of total availability—$30 million committed with an accordion option to increase availability by $20 million. The facility matures on January 2, 2029, and, as of closing, carries a zero balance drawdown, reflecting the company’s confidence in its existing cash reserves and projected cash flows to fund organic growth. Interest rates under the facility are determined by a pricing grid tied to leverage: loans bear either Term SOFR plus a spread of 150 to 225 basis points or the Alternate Base Rate plus 50 to 125 basis points. Unused commitment fees range from 0.225% to 0.30%, with no upfront fee assessed, underscoring LifeMD’s strong credit profile and providing substantial financial flexibility for potential corporate development or shareholder value initiatives.

LifeMD has integrated Novo Nordisk’s newly approved Wegovy® pill—the first oral GLP-1 therapy authorized for chronic weight management and cardiovascular risk reduction—into its virtual care platform. Eligible patients can access 1.5mg and 4mg doses at $149 per month, rising to $199 for 4mg and $299 for 9mg and 25mg doses after April 15, 2026. The FDA’s December 22, 2025 approval follows a 64-week Phase 3 trial in which once-daily oral semaglutide plus diet and exercise achieved 16.6% mean weight loss versus 2.7% with placebo. The collaboration further positions LifeMD as a preferred telehealth provider for branded obesity treatments, leveraging its proprietary digital care platform, 50-state medical group, and integrated pharmacy fulfillment to deliver end-to-end clinical oversight and home delivery of GLP-1 therapies.